SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (2875)6/2/2010 12:10:27 PM
From: Jibacoa  Read Replies (1) | Respond to of 3722
 
NYMX reversed yesterday's loss and was up earlier 19.61%.<g>
It is still up 15.07% at present. Volume is moderate, but > 67Ks which is > its ADV.

However, it still was unable to go above the resistance at the $5 level.<g>

bigcharts.marketwatch.com

NYMX showed a good improvement on revenues on the 4thQ & on the 1stQ, but has not been able to trim its losses.

It presented some new positive data on NX-1207 at the American Urological Association Annual Meeting in Frisco.

It said that it has completed a series of blinded controlled multi-center trials where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs.

It also said that further follow-up studies have shown evidence of long lasting benefit with a significant number of patients that received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 6 1/2 Yrs.

finance.yahoo.com

NYMX has no significant LTD, but has been burning its cash at a good clip and may need new financing.<g>
The insiders reportedly hold a good % of the stock.

It has a good amount of resistance at $5 and also at the $6 level.
There is no ACTAY. It seems better to wait for further developments.<g>

bigcharts.marketwatch.com

Bernard